Search clinical trials for: AZD4831

Total 105 results

AstraZeneca

Terminated

A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects

Cardiovascular Disease
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% (ENDEAVOR)

Heart Failure With Preserved Ejection Fraction

United States, France, Netherlands, Belgium, Taiwan, Slovakia, Japan, Czechia, Hungary, Australia, Bulgaria, Poland, Russian Federation, Brazil, Denmark, Turkey, Sweden, Canada
AstraZeneca
Parexel

Completed

A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

Healthy Volunteers

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers

Renal Impairment

Bulgaria
AstraZeneca

Recruiting

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. (CRESCENDO)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Denmark, Germany, South Africa, Spain, United Kingdom, Italy, Argentina, Bulgaria, Mexico, Turkey, Poland, Netherlands
AstraZeneca

Terminated

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure. (SATELLITE)

Heart Failure

Denmark, Finland, Netherlands, United States, Sweden
Mayo Clinic
National Center for Advancing Translational Sciences (NCATS)

Completed

MPO Inhibitor A_Zeneca for HFpEF

Heart Failure

United States
AstraZeneca

Completed

A Study in Participants With Non-cirrhotic NASH With Fibrosis (COSMOS)

Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Denmark, Italy, Spain, United States, Argentina, Sweden, Mexico, Norway, Portugal
AstraZeneca
Parexel

Completed

A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease

Cardiovascular Disease

United States
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831

Cardiovascular Disease

United Kingdom
AstraZeneca

Recruiting

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

Hepatic Impairment

United States
AstraZeneca

Completed

Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

Healthy Volunteers | Alzheimer's Disease | Tolerability | Safety | Blood Concentration

United Kingdom
AstraZeneca

Completed

Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels

Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax

United Kingdom
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United Kingdom, Korea, Republic of, Australia, United States, Spain
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833

Healthy Volunteers

United Kingdom
AstraZeneca

Active, not recruiting

A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

ER+ HER2- Advanced Breast Cancer

Japan
Samsung Medical Center
AstraZeneca

Terminated

AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]

Small Cell Lung Cancer

Korea, Republic of
AstraZeneca

Completed

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

Carcinoma | Cancer | Tumors

Japan
AstraZeneca

Completed

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder

United States, United Kingdom, Germany
AstraZeneca

Not yet recruiting

LTFU for All Cell and Gene Therapy Studies (LOCUS)

Hepatocellular Carcinoma | Prostate Cancer

United States
AstraZeneca
National Institutes of Health (NIH); Eolas Therapeutics INC.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers

Smoking Cessation

United States
AstraZeneca

Completed

Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (TOP)

Chronic Obstructive Pulmonary Disease (COPD)

Sweden, Denmark, Finland, Netherlands, Norway
AstraZeneca

Completed

Study of AZD8931 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Russian Federation, Germany
AstraZeneca

Completed

A Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets

Healthy

United Kingdom
AstraZeneca

Terminated

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

Lymphoma | Non-Hodgkin Lymphoma | NHL

United States
AstraZeneca

Completed

Pharmacokinetics of Extended-Release Test- and Reference Formulations of AZD0837

Healthy

Sweden
AstraZeneca

Completed

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

Neoplasms

United States
AstraZeneca

Completed

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
AstraZeneca

Completed

A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.

Advanced Solid Tumours

United States
AstraZeneca

Completed

A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females

Healthy

United Kingdom
AstraZeneca

Terminated

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

Lymphoma

United States, Canada
AstraZeneca

Terminated

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States, Canada
AstraZeneca

Completed

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451 (AZD4451 SAD)

Bipolar Disorder

United States
AstraZeneca

Withdrawn

Assessment of the Safety and Pharmacokinetics of Single and Multiple Oral Doses of AZD4316 in Healthy Subjects

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Hepatic Impairment

United States, Bulgaria, Slovakia
AstraZeneca

Completed

Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931

Healthy

United Kingdom
AstraZeneca

Completed

Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers

Healthy

Japan
AstraZeneca

Completed

AZD0837 Extended Release (ER) Japan Study (ER J ph I)

Healthy

Japan
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069

Chronic Obstructive Pulmonary Disease (COPD).

United Kingdom
AstraZeneca
Quotient Sciences

Completed

AZD4635 Relative Bioavailability Study (Rel Bio)

Healthy Volunteers

United Kingdom
AstraZeneca

Active, not recruiting

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (SERENA-1)

ER+ HER2- Advanced Breast Cancer

United States, Spain, United Kingdom
AstraZeneca

Completed

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer (SERENA-3)

HER2-negative Breast Cancer

Mexico, United Kingdom, Georgia
AstraZeneca

Completed

Excretion of Radiolabelled AZD0837

Healthy

Sweden
AstraZeneca
Parexel

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects

Chronic Obstructive Pulmonary Disease

United Kingdom
AstraZeneca
Parexel; Covance; The Doctors Laboratory; Industrias Farmacéuticas Almirall S.A.

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects

Chronic Obstructive Pulmonary Disease - COPD

United Kingdom
AstraZeneca

Completed

Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects

Asthma (Part 1) | COPD (Part 2)

United Kingdom
AstraZeneca

Completed

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Bladder Cancer | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer | Transitional Cell Bladder Cancer

United States, Spain, United Kingdom, Germany, Canada
AstraZeneca
Parexel

Completed

Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871

Chronic Obstructive Pulmonary Disease COPD

Germany, United Kingdom
AstraZeneca
Altasciences Company Inc.

Completed

A Safety Study of AZD4041 in Healthy Participants

Opioid Use Disorder (OUD)

Canada

3

Subscribe